PL4321175T3 - Magnetyczne nanokapsuły polimerowe nadające się do stosowania w terapii, zwłaszcza antynowotworowej - Google Patents

Magnetyczne nanokapsuły polimerowe nadające się do stosowania w terapii, zwłaszcza antynowotworowej

Info

Publication number
PL4321175T3
PL4321175T3 PL22461593.0T PL22461593T PL4321175T3 PL 4321175 T3 PL4321175 T3 PL 4321175T3 PL 22461593 T PL22461593 T PL 22461593T PL 4321175 T3 PL4321175 T3 PL 4321175T3
Authority
PL
Poland
Prior art keywords
cancer
therapy
ones
magnetic polymer
especially anti
Prior art date
Application number
PL22461593.0T
Other languages
English (en)
Inventor
Szczepan Zapotoczny
Joanna ODROBIŃSKA-BALIŚ
Elżbieta GUMIENICZEK-CHŁOPEK
Czesław Kapusta
Original Assignee
Chde Polska S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chde Polska S.A. filed Critical Chde Polska S.A.
Publication of PL4321175T3 publication Critical patent/PL4321175T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL22461593.0T 2022-08-11 2022-08-11 Magnetyczne nanokapsuły polimerowe nadające się do stosowania w terapii, zwłaszcza antynowotworowej PL4321175T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22461593.0A EP4321175B1 (en) 2022-08-11 2022-08-11 Magnetic polymer nanocapsules suitable for use in therapy, especially anti-cancer ones

Publications (1)

Publication Number Publication Date
PL4321175T3 true PL4321175T3 (pl) 2025-12-22

Family

ID=83598584

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22461593.0T PL4321175T3 (pl) 2022-08-11 2022-08-11 Magnetyczne nanokapsuły polimerowe nadające się do stosowania w terapii, zwłaszcza antynowotworowej

Country Status (7)

Country Link
EP (1) EP4321175B1 (pl)
JP (1) JP2025527328A (pl)
KR (1) KR20250065609A (pl)
CN (1) CN120475993A (pl)
CA (1) CA3264708A1 (pl)
PL (1) PL4321175T3 (pl)
WO (1) WO2024033546A1 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI538701B (zh) 2015-01-13 2016-06-21 國立清華大學 用於藥物傳遞的蛋白質奈米磁性殼核膠囊及其應用
PL229276B1 (pl) 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
PL240632B1 (pl) 2018-04-06 2022-05-09 Univ Jagiellonski Zastosowanie nanokapsuły z ciekłym rdzeniem olejowym w terapii przeciwnowotworowej

Also Published As

Publication number Publication date
CA3264708A1 (en) 2024-02-15
WO2024033546A1 (en) 2024-02-15
EP4321175B1 (en) 2025-07-16
KR20250065609A (ko) 2025-05-13
CN120475993A (zh) 2025-08-12
JP2025527328A (ja) 2025-08-20
EP4321175A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
Mirzaei et al. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX378635B (es) Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
EP4461308A3 (en) Toxicity management for anti-tumor activity of cars
PL3069728T3 (pl) Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
WO2009156117A3 (de) Vorrichtung zur magnetfeldtherapie
WO2012086991A3 (ko) 광 치료장치 및 이의 제어방법
WO2013120038A3 (en) Morpholino targeting dux4 for treating fshd
MX2016011295A (es) Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2.
ES2723827T3 (es) Terapia de combinación de fármacos para el tratamiento de tumores sólidos
MY173310A (en) Cationic polymers for treating construction aggregates
EP4268900A3 (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
WO2015112850A3 (en) Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
LT3917538T (lt) Deoksi-citidino dariniai, skirti panaudoti vėžio terapijose
WO2011011061A3 (en) Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
WO2011017096A3 (en) Methods of treating hematologic cancers
BR112013019674A2 (pt) método para remoção de metoxipirazinas de vinho e/ou suco, para a remoção de compostos indesejáveis no vinho e/ou suco, para a modificação do perfil organoléptico de vinho e/ou suco e para a remoção de um composto-alvo de vinho e/ou suco
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
WO2005123908A3 (en) Novel cancer cell lines and uses thereof
GB201202600D0 (en) Machine for flash-butt welding of rails
EP4043583A4 (en) BIOMARKERS, METHODS, KIT AND ARRAY FOR PREDICTING THERAPEUTIC EFFECTS OF BCG-INTRAVESIC INFUSION THERAPY FOR TREATING BLADDER CANCER
EP4349410A3 (en) A composition for use in the therapeutic treatment of a cancer or a tumor
WO2008108647A3 (en) Enhancement of anticancer therapy by flavonoids
MX2012007797A (es) Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.